ARRY strengthens scientific team
Array BioPharma Announces Key Additions To Scientific Leadership
Appoints Nicholas A. Saccomano, Ph.D. as Chief Scientific Officer and Robert E. Winkler, M.D. as Vice President of Clinical Development
PR Newswire
Array BioPharma Inc. May 19, 2014 3:00 PM
BOULDER, Colo., May 19, 2014 /PRNewswire/ -- Array BioPharma Inc. (ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced the appointments of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer and Robert E. Winkler, M.D., as Vice President of Clinical Research and Development. Dr. Saccomano will oversee Array's discovery efforts and chemistry, manufacturing and controls (CMC) activities as a member of the executive management team, reporting to Array's Chief Executive Officer, Ron Squarer. Dr. Winkler will be responsible for leading the company's clinical science and operations activities, including its late-stage multiple myeloma program, filanesib, reporting to Array's Chief Medical Officer, Michael Needle, M.D.
View gallery
.
Nicholas A. Saccomano, Ph.D., appointed Chief Scientific Officer at Array BioPharma Inc.
"We are pleased to have Nick and Robert join the Array team," said Mr. Squarer. "Nick has a proven track record in drug discovery from his tenure at Pfizer as an executive and ultimately a Senior Vice President in R&D. He will play a critical role in identifying and developing opportunities to expand our discovery collaboration business. Robert brings significant experience in advancing drugs through development, which will be key as we look to initiate a Phase 3 trial with our lead multiple myeloma program later this year."
"I am impressed with the consistent productivity of Array's discovery team, inventing approximately 18 drugs that have advanced into clinical development since the company's inception, as well as its impressive roster of alliance partners," said Dr. Saccomano. "I look forward to working with this talented team as we look to broaden our collaborative outreach and build on an already outstanding track record of drug discovery."
Dr. Saccomano is a seasoned leader and mentor with 30 years of experience in pharmaceutical and biotechnology research and development, with expertise in discovery research, clinical development, portfolio strategy, technology and clinical candidate licensing, and scientific partnering. Dr. Saccomano most recently served as Chief Technology Officer at SomaLogic, Inc. and as Chief Scientific Officer at Bend Research Inc. While at Pfizer Inc., Dr. Saccomano held positions of increasing responsibility, including Senior Vice President in the R&D organization and Vice President of Discovery Technology. As head of discovery technology, he managed and developed a diverse set of enabling technologies used broadly across the drug discovery pipeline. During his tenure, he also directed medicinal sciences, drug discovery and strategic alliances. Dr. Saccomano obtained his Ph.D. in chemistry from Columbia University under the direction of Professor Gilbert Stork.
Dr. Winkler developed expertise in drug development strategy and execution, clinical pharmacology, as well as planning regulatory strategy and leading successful negotiations with health authorities, through his 15 years of diverse global assignments in the biotech and pharmaceutical industries. Dr. Winkler most recently served as Vice President of Global Clinical Development and Operations at Aptalis Pharma, which was recently acquired by Forest Labs, where he led the company's drug development programs. Prior to this, Dr. Winkler held positions of increasing responsibility at Amicus Therapeutics, serving as Vice President of Clinical Research and Operations, leading drug development and regulatory preparations in rare genetic diseases. Dr. Winkler served as a Senior Global Clinical Leader at Novartis Oncology, securing regulatory approvals for Afinitor® (everolimus) for Neuroendocrine Tumors through an Oncology Drug Advisory Committee, a blockbuster product that has surpassed $1 billion in annual sales, as well as an sNDA for Sandostatin® another key Novartis Oncology blockbuster. Preceding Novartis, Dr. Winkler held roles of increasing responsibility at Schering-Plough, where he focused on expanding lifecycle opportunities for PegIntron®. Dr. Winkler obtained his Medical and Bachelor of Science degrees from the Hebrew University Hadassah Medical School in Israel.
Bladerunner
News 
Market Data 
Discover 
